US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
EP1473292A1
(en)
*
|
1997-11-03 |
2004-11-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
WO1999023091A1
(en)
*
|
1997-11-03 |
1999-05-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
EP1041982B1
(en)
*
|
1997-12-22 |
2011-10-19 |
Bayer HealthCare LLC |
INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
|
PL341356A1
(en)
*
|
1997-12-22 |
2001-04-09 |
Bayer Ag |
Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
DK1690853T3
(da)
*
|
1999-01-13 |
2010-06-07 |
Bayer Healthcare Llc |
Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
*
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
EP1157026A1
(en)
|
1999-02-22 |
2001-11-28 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
JP2002539206A
(ja)
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
KR100709497B1
(ko)
|
1999-03-12 |
2007-04-20 |
베링거 인겔하임 파마슈티칼즈, 인코포레이티드 |
소염제로서 유용한 화합물 및 이의 제조방법
|
DE60024830T2
(de)
|
1999-07-09 |
2006-06-14 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
MXPA02004594A
(es)
|
1999-11-16 |
2002-10-23 |
Boehringer Ingelheim Pharma |
Derivados de urea como agentes anti-inflamatorios.
|
WO2001038312A1
(en)
|
1999-11-23 |
2001-05-31 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
JP2003528084A
(ja)
*
|
2000-03-22 |
2003-09-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
p38のインヒビター
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
EP1415987B1
(en)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Nitrogenous aromatic ring compounds as anti cancer agents
|
EP1341771A2
(en)
|
2000-11-29 |
2003-09-10 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
WO2002070467A1
(en)
|
2001-02-26 |
2002-09-12 |
4Sc Ag |
Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
|
DE10109204A1
(de)
*
|
2001-02-26 |
2002-09-19 |
4Sc Ag |
Verbindungen zur Behandlung von Protozoen-Erkrankungen
|
CA2445003A1
(en)
|
2001-05-16 |
2002-11-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Diarylurea derivatives useful as anti-inflammatory agents
|
WO2002096876A1
(en)
|
2001-05-25 |
2002-12-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
ES2269709T3
(es)
|
2001-06-05 |
2007-04-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compuestos de cicloalquil-urea, fusionada con grupos benzo y 1,4-disustituida.
|
CA2453147A1
(en)
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
WO2003032989A1
(en)
|
2001-10-18 |
2003-04-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
DE10203086A1
(de)
*
|
2002-01-28 |
2003-07-31 |
Bayer Ag |
5-Ring Heterozyklen
|
WO2003068223A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
AU2003209116A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
ATE386030T1
(de)
|
2002-02-25 |
2008-03-15 |
Boehringer Ingelheim Pharma |
1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
|
EP1707205A2
(en)
|
2002-07-09 |
2006-10-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
WO2004014870A1
(en)
|
2002-08-08 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
US7268139B2
(en)
|
2002-08-29 |
2007-09-11 |
Scios, Inc. |
Methods of promoting osteogenesis
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
CA2516931C
(en)
|
2003-02-28 |
2014-09-09 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
WO2004085433A2
(en)
*
|
2003-03-28 |
2004-10-07 |
Pharmacia & Upjohn Company Llc |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
GB0320244D0
(en)
*
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
JP4860474B2
(ja)
|
2003-05-20 |
2012-01-25 |
バイエル、ファーマシューテイカルズ、コーポレイション |
Pdgfrによって仲介される病気のためのジアリール尿素
|
DK1663978T3
(da)
|
2003-07-23 |
2008-04-07 |
Bayer Pharmaceuticals Corp |
Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
|
MXPA06002853A
(es)
|
2003-09-11 |
2006-06-14 |
Kemia Inc |
Inhibidores citoquina.
|
WO2005030091A2
(en)
|
2003-09-25 |
2005-04-07 |
Scios Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
WO2005110994A2
(en)
|
2004-04-30 |
2005-11-24 |
Bayer Pharmaceuticals Corporation |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
EP1828169A2
(en)
|
2004-12-07 |
2007-09-05 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
US20080081833A1
(en)
*
|
2004-12-20 |
2008-04-03 |
Astrazeneca Ab |
Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
|
AU2005321946B2
(en)
*
|
2004-12-23 |
2012-08-16 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
GB0500435D0
(en)
*
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
UA93673C2
(ru)
|
2005-03-07 |
2011-03-10 |
Баер Шеринг Фарма Акциенгезельшафт |
Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
|
DE102005015253A1
(de)
*
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
DE102005037499A1
(de)
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
JP2009513649A
(ja)
*
|
2005-10-28 |
2009-04-02 |
イーライ リリー アンド カンパニー |
キナーゼ阻害剤
|
TWI325423B
(en)
*
|
2005-10-28 |
2010-06-01 |
Lilly Co Eli |
Kinase inhibitors
|
US8580798B2
(en)
|
2005-12-21 |
2013-11-12 |
Bayer Intellectual Property Gmbh |
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
|
JP5190361B2
(ja)
|
2006-05-18 |
2013-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
甲状腺癌に対する抗腫瘍剤
|
EP2338488A1
(en)
|
2006-05-26 |
2011-06-29 |
Bayer HealthCare, LLC |
Drug combinations with substituted diaryl ureas for the treatment of cancer
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
CA2672951A1
(en)
|
2006-12-20 |
2008-07-03 |
Bayer Healthcare Llc |
Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
|
AU2008211952B2
(en)
|
2007-01-29 |
2012-07-19 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
JP5396379B2
(ja)
|
2007-04-02 |
2014-01-22 |
エボテック・アーゲー |
ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用
|
EP2146718A4
(en)
|
2007-04-20 |
2010-08-11 |
Deciphera Pharmaceuticals Llc |
KINASEHEMMER FOR THE TREATMENT OF MYELOPROLIFERATIVE AND OTHER PROLIFERATIVE DISEASES
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
WO2010038086A2
(en)
|
2008-10-02 |
2010-04-08 |
Respivert Limited |
Novel compounds
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
CN102333770B
(zh)
|
2008-12-11 |
2015-01-28 |
瑞斯比维特有限公司 |
P38map激酶抑制剂
|
CN102317442B
(zh)
|
2008-12-17 |
2014-08-13 |
斯克里普斯研究所 |
干细胞的产生和保持
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
EP2556067B1
(en)
|
2010-04-08 |
2016-02-24 |
Respivert Limited |
Pyrazolyl ureas as p38 map kinase inhibitors
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012012404A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
CN108329246B
(zh)
*
|
2011-05-13 |
2021-02-26 |
阵列生物制药公司 |
作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
BR112014007694B1
(pt)
|
2011-10-03 |
2022-09-27 |
Respivert Limited |
Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
JP2015503505A
(ja)
*
|
2011-12-23 |
2015-02-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
ヘテロアリールおよびその使用
|
EP2799537B1
(en)
|
2011-12-28 |
2021-09-22 |
Kyoto Prefectural Public University Corporation |
Normalization of culture of corneal endothelial cells
|
WO2013162027A1
(ja)
|
2012-04-27 |
2013-10-31 |
学校法人 慶應義塾 |
神経分化促進剤
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
CN107857755B
(zh)
|
2012-11-13 |
2020-10-27 |
阵列生物制药公司 |
作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
|
PL2920166T3
(pl)
|
2012-11-13 |
2017-05-31 |
Array Biopharma, Inc. |
Bicykliczne związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny przydatne w leczeniu bólu
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078331A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014098176A1
(ja)
|
2012-12-21 |
2014-06-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
US20160016934A1
(en)
|
2013-03-14 |
2016-01-21 |
Respivert Limited |
Kinase inhibitors
|
KR102204279B1
(ko)
|
2013-05-14 |
2021-01-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
|
US9750723B2
(en)
|
2013-10-31 |
2017-09-05 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
CA2928626C
(en)
|
2013-11-14 |
2023-03-14 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
TWI751099B
(zh)
|
2014-02-14 |
2022-01-01 |
英商瑞斯比維特有限公司 |
作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途
|
HUE045340T2
(hu)
|
2014-05-15 |
2019-12-30 |
Array Biopharma Inc |
1-((3S,4R)-4-(3-fluorfenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2- metilpirimidin-5-il)-1-fenil-1H-pirazol-5-il)karbamid mint TrkA kináz inhibitor
|
US20170202818A1
(en)
|
2014-07-18 |
2017-07-20 |
Ohio University |
Methods and compositions to modify gsk-3 activity
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
JP6757959B2
(ja)
|
2015-06-16 |
2020-09-23 |
株式会社 PRISM BioLab |
抗がん剤
|
SG11202007198WA
(en)
|
2018-01-31 |
2020-08-28 |
Deciphera Pharmaceuticals Llc |
Combination therapy for the treatment of gastrointestinal stromal tumors
|
PT3762368T
(pt)
|
2018-03-08 |
2022-05-06 |
Incyte Corp |
Compostos de aminopirazina diol como inibidores de pi3k-y
|
EP3773579A4
(en)
|
2018-03-26 |
2022-03-09 |
Clear Creek Bio, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
BR112022002609A2
(pt)
|
2019-08-12 |
2022-08-09 |
Deciphera Pharmaceuticals Llc |
Métodos de tratamento de tumores estromais gastrointestinais
|
TW202122082A
(zh)
|
2019-08-12 |
2021-06-16 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
IL293866A
(en)
|
2019-12-30 |
2022-08-01 |
Deciphera Pharmaceuticals Llc |
Compositions of amorphous kinase inhibitors and methods of using them
|
KR20220123058A
(ko)
|
2019-12-30 |
2022-09-05 |
데시페라 파마슈티칼스, 엘엘씨. |
1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|